© PR Newswire
15.05.2025
REC
LISTED
EURONEXT
RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING--THE EXPANDED INDICATION FOR ISTURISA® (OSILODROSTAT) FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM
News Preview
ISTURISA® (osilodrostat) is a cortisol synthesis inhibitor that blocks the enzyme 11beta-hydroxylase to help normalize hypercortisolemia in Cushing's syndrome, a rare endocrine condition that can have significant impact on patients and their familiesThe expanded indication is supported by an extensive clinical development programMILAN and BRIDGEW...
Themefolio
Profiler
Peergroup
© ActuNews
15.05.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – May 15, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
Oxurion received a transparency notification on May 15, 2025, from Atlas Spe...
Themefolio
Profiler
Peergroup
© ActuNews
15.05.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 15 mei 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgevingen heeft ontvangen:
Oxurion ontving een transparant...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
15.05.2025
KDEV
LISTED
STO
Karolinska Development’s Annual General Meeting 2025
News Preview
STOCKHOLM, SWEDEN – May 15, 2025. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held the Annual General Meeting on May 15, 2025. The shareholders have had the right to exercise their voting rights in advance through postal voting pursuant to item 13 in the articles of association. Therefore, shareholders have had the...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© BusinessWire
15.05.2025
LIVN
LISTED
NASDAQ
LivaNova to Present at the Jefferies Global Healthcare Conference
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The presentation will take place Thurs., June 5, at 3:10 p.m. Eastern Time.
The discussion will be available to all i...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
SLP
LISTED
NASDAQ
Simulations Plus Releases DILIsym® 11
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of DILIsym® 11, the latest version of its flagship quantitative systems toxicology (QST) platfo...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
HELP
LISTED
NASDAQ
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has engaged Thermo Fisher Scientific (“Thermo Fisher”), the world leader in servi...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2025
AMRX
LISTED
NASDAQ
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
News Preview
BRIDGEWATER, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya® (dihydroergotamine mesylate) injection, the first and only dihydroergotamine (DHE) autoinjector for the acute treatment of migraine with...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRA...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2025
TRAW
LISTED
NASDAQ
Traws Pharma Reports First Quarter 2025 Results and Business Highlights
News Preview
FDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated approval utilizing the “Animal Rule”...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2025
POAI
LISTED
NASDAQ
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update...
Themefolio
Profiler
Peergroup
© PR Newswire
15.05.2025
BIOA B
LISTED
STO
Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026)
News Preview
STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 (April 2025 through March 2026), corresponding to a 73 percent growth compared to the previous year. This w...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
15.05.2025
BIOA B
LISTED
STO
Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026)
News Preview
STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 (April 2025 through March 2026), corresponding to a 73 percent growth compared to the previous year. This w...
Themefolio
Profiler
Peergroup
© PR Newswire
15.05.2025
SECT_B
LISTED
STO
Guelph General Hospital adds digital pathology to cloud service from Sectra--enables integrated diagnostics for improved patient care
News Preview
LINKÖPING, Sweden and MISSISSAUGA, ON, May 15, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) announces that Guelph General Hospital in Canada will be the first in the country to add Sectra's digital pathology module to its current cloud service, Sectra One Cloud. This addition will provide pa...
Themefolio
Profiler
Peergroup
© EQS Newswire
15.05.2025
1SXP
LISTED
XETR
SCHOTT Pharma delivers strong second quarter of fiscal year 2025
News Preview
SCHOTT Pharma delivers strong second quarter of fiscal year 2025
Q2 2025 revenues up 8% yoy to EUR 252m; increase of 10% yoy at constant currencies
Q2 2025 EBITDA margin of 28.6% as reported and 28.2% at constant currencies
Share of strong-margin high-value solutions (HVS) at 56% in Q2 2025
SCHOTT Pharma reaffirms FY 2025 guidance
SCHOTT Pharma......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.05.2025
1SXP
LISTED
XETR
SCHOTT Pharma schließt starkes zweites Quartal im Geschäftsjahr 2025 ab
News Preview
SCHOTT Pharma schließt starkes zweites Quartal im Geschäftsjahr 2025 ab
Umsatz in Q2 2025 um 8 % auf 252 Mio. Euro gestiegen; währungsbereinigtes Wachstum von 10 % gegenüber dem Vorjahr
EBITDA-Marge in Q2 2025 berichtet bei 28,6 % und währungsbereinigt bei 28,2 %
Anteil margenstarker High-Value-Lösungen (HVS) in Q2 2025 bei 56 %
SCHOTT Pharma b......
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2025
GNFT
LISTED
EURONEXT
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the publication of its 2025 Extra-Financial Performance Report (fiscal year 2024)....
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2025
CLARI
LISTED
EURONEXT
Minutes of the General Meeting of 14 May 2025 and additional information on the plan to reinforce the financial position
News Preview
Attachment...
Themefolio
Profiler
Peergroup
© BusinessWire
14.05.2025
BLUE
LISTED
NASDAQ
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), Carlyle (NASDAQ: CG) (“Carlyle”) and SK Capital Partners, LP (“SK Capital”) today announced they have amended their definitive agreement pursuant to which Carlyle and SK Capital will purchase all of the outstanding shares of bluebird. Under the terms of the amended agreement bluebird stockholders can...
Themefolio
Profiler
Peergroup
© BusinessWire
14.05.2025
TEM
LISTED
NASDAQ
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new strategic collaboration to advance Boehringer Ingelheim’s growing cancer pipeline. The new, multi-year collaboration builds on foundational work the two companies have conducted in the last few years,...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2025
GMAB
LISTED
CPH
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress
News Preview
Media ReleaseCOPENHAGEN, Denmark; May 14, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2025
AUTL
LISTED
NASDAQ
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
News Preview
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress...
Themefolio
Profiler
Peergroup
© BusinessWire
14.05.2025
HELP
LISTED
NASDAQ
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a firesid...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.05.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
News Preview
With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments...
Themefolio
Profiler
Peergroup
© PR Newswire
14.05.2025
HNSA
LISTED
STO
Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS
News Preview
LUND, Sweden, May 14, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) at the Peripheral Nerve Society (PNS) Annual Meeting, taking place 17-20 May in Edinburgh, Scotlan...
Themefolio
Profiler
Peergroup
© PR Newswire
14.05.2025
HNSA
LISTED
STO
Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS
News Preview
LUND, Sweden, May 14, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) at the Peripheral Nerve Society (PNS) Annual Meeting, taking place 17-20 May in Edinburgh, Scotlan...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
TEM
LISTED
NASDAQ
Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral presentation, at the 2025 annual meeting of the Professional Society for Health Economics and Outcomes Research (ISPOR), taking place May 13-16 in Montreal,...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
ERF
LISTED
EURONEXT
Eurofins Scientific: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY...
Themefolio
Profiler
Peergroup
© ActuNews
13.05.2025
ALTHX
LISTED
EURONEXT
THERANEXUS AND BEYOND BATTEN DISEASE FOUNDATION ANNOUNCE STRONG POSITIVE REAL-WORLD DATA SUPPORTING BATTEN-1 EFFICACY FOR THE TREATMENT OF BATTEN DISEASE
News Preview
Lyon, France – Austin, Texas, United States – Mai 13, 2025 – 6.00 pm CET – Theranexus, a biopharmaceutical company developing drug candidates for rare neurological diseases and the Beyond Batten Disease Foundation (BBDF), today announced new real-world data strongly supporting the efficacy of Batten-1 (miglustat) as a treatm...
Themefolio
Profiler
Peergroup
© ActuNews
13.05.2025
ALTHX
LISTED
EURONEXT
THERANEXUS ET LA FONDATION BEYOND BATTEN DISEASE ANNONCENT DES DONNÉES EN VIE RÉELLE TRÈS POSITIVES SOUTENANT L'EFFICACITÉ DE BATTEN-1 DANS LE TRAITEMENT DE LA MALADIE DE BATTEN CLN3
News Preview
Lyon, France – Austin, Texas, États-Unis – 13 mai 2025 – 18h00 – Theranexus, société biopharmaceutique développant des candidats médicaments pour les maladies neurologiques rares, et la Fondation Beyond Batten Disease (BBDF), annoncent aujourd'hui de nouvelles données issues de l...
Themefolio
Profiler
Peergroup
© PR Newswire
13.05.2025
INDV
LISTED
NASDAQ
Indivior to Participate in Upcoming Investor Events
News Preview
RICHMOND, Va., May 13, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events:
Jefferies Global Healthcare Conference – New York City, NYJoe Ciaffoni, Chief Ex...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
13.05.2025
ALTHX
LISTED
EURONEXT
Theranexus and Beyond Batten Disease Foundation Announce Strong Positive Real-World Data Supporting Batten-1 Efficacy for the Treatment of Batten Disease
News Preview
LYON, FRANCE and AUSTIN, TX / ACCESS Newswire / May 13, 2025 / Theranexus, a biopharmaceutical company developing drug candidates for rare neurological diseases, and the Beyond Batten Disease Foundation (BBDF) today announced new real-world data strongly supporting the efficacy of Batten-1 (miglustat) as a treatment for CLN3 disease, also known as...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
DFTX
LISTED
NASDAQ
MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at the 2025 RBC Capital Markets Global Healthcare Conference:
2025 RBC Capital Ma...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.05.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
News Preview
- In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.05.2025
LEGN
LISTED
NASDAQ
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
News Preview
SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2025 unaudited financial results and key corporate highlights....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.05.2025
TIL
LISTED
NASDAQ
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
13.05.2025
BIOA B
LISTED
STO
Invitation to presentation of BioArctic's first quarter report for January - March 2025 on May 21 at 9.30 a.m. CET
News Preview
STOCKHOLM, May 13, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's first quarter report for January - March 2025 on Wednesday, May 21, 2025, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on May 21, a...
Themefolio
Profiler
Peergroup
© PR Newswire
13.05.2025
BIOA B
LISTED
STO
Invitation to presentation of BioArctic's first quarter report for January - March 2025 on May 21 at 9.30 a.m. CET
News Preview
STOCKHOLM, May 13, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company's first quarter report for January - March 2025 on Wednesday, May 21, 2025, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on May 21, a...
Themefolio
Profiler
Peergroup
© PR Newswire
13.05.2025
HNSA
LISTED
STO
Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
News Preview
LUND, Sweden, May 13, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that Maria Törnsén has been appointed Chief Operating Officer (COO) and President U.S. effective 19 May. Ms Törnsén will report to CEO Renée Aguiar-Lucander and be a member of the Executive Committee.
Maria Törnsén has more than 20 yea...
Themefolio
Profiler
Peergroup
© PR Newswire
13.05.2025
HNSA
LISTED
STO
Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
News Preview
LUND, Sweden, May 13, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that Maria Törnsén has been appointed Chief Operating Officer (COO) and President U.S. effective 19 May. Ms Törnsén will report to CEO Renée Aguiar-Lucander and be a member of the Executive Committee.
Maria Törnsén has more than 20 yea...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.05.2025
ILM1
LISTED
XETR
Medios starts 2025 financial year successfully with significant increase in earnings
News Preview
Press release
Medios starts 2025 financial year successfully with significant increase in earnings
Revenue up 6.2% to €484.7 million in the first quarter
Significantly higher increase in EBITDA pre1 of 52.9% to €23.1 million with margin improvement to 4.8%
Earnings per share increased to €0.25 from €0.17 in Q1 2024
2025 forecast confirmed: Fur......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.05.2025
ILM1
LISTED
XETR
Medios startet mit deutlicher Ergebnissteigerung erfolgreich ins Geschäftsjahr 2025
News Preview
Pressemitteilung
Medios startet mit deutlicher Ergebnissteigerung erfolgreich ins Geschäftsjahr 2025
Umsatzsteigerung im ersten Quartal um 6,2 % auf 484,7 Mio. €
Signifikant überproportionaler Anstieg des EBITDA pre1 um 52,9 % auf 23,1 Mio. € mit Margenverbesserung auf 4,8 %
Ergebnis je Aktie erhöht sich auf 0,25 € von 0,17 € in Q1 2024
Prog......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.05.2025
EUZ
LISTED
XETR
Eckert & Ziegler Starts with Earnings Growth in Q1 2025 and Confirms Full-Year Forecast
News Preview
1st Quarter 2025:
Sales of € 68.2 million (previous year: € 67.6 million)
EBIT before special items of € 16.2 million (previous year: € 15.0 million)
Net income of 9.7 Mio. € (previous year: € 8.5 million)
Forecast 2025:
Sales of around € 320 million (confirmed)
EBIT before special items of around € 78 million (confirmed)
Berlin, 13 May 2025......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.05.2025
EUZ
LISTED
XETR
Eckert & Ziegler startet mit Ergebniswachstum in Q1 2025 und bestätigt Jahresprognose
News Preview
1. Quartal 2025:
Umsatz 68,2 Mio. € (VJ: 67,6 Mio. €)
EBIT vor Sondereinflüssen 16,2 Mio. € (VJ:15,0 Mio. €)
Nettogewinn 9,7 Mio. € (VJ: 8,5 Mio. €)
Jahresprognose 2025:
Umsatz von rund 320 Mio. € (bestätigt)
EBIT vor Sondereinflüssen von rund 78 Mio. € (bestätigt)
Berlin, den 13. Mai 2025. Die Eckert & Ziegler SE (ISIN DE0005659700, Tec......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.05.2025
SOON
LISTED
SIX
Sonova publishes Annual Report 2024/25
News Preview
Group Media & Investor ReleaseAd hoc announcement pursuant to Art. 53 LR
Staefa (Switzerland), May 13, 2025 – Sonova Holding AG (SWX: SOON), a leading provider of innovative hearing solutions, today publishes its Annual Report for the 2024/25 financial year, presenting audited results for the financial year ending March 31, 2025. The report ref......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.05.2025
SOON
LISTED
SIX
Sonova veröffentlicht Geschäftsbericht 2024/25
News Preview
Group Media & Investor ReleaseAd hoc-Mitteilung gemäss Art. 53 KR
Stäfa (Schweiz), 13. Mai 2025 – Die Sonova Holding AG (SWX: SOON), ein führender Anbieter innovativer Hörlösungen, veröffentlicht heute ihren Geschäftsbericht 2024/25. Dieser enthält den geprüften Jahresabschluss für das Geschäftsjahr 2024/25, das am 31. März 2025 endete. Er spie......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.05.2025
AFX
LISTED
XETR
Carl Zeiss Meditec achieves revenue growth and stable operating profit in the first six months of 2024/25
News Preview
Carl Zeiss Meditec achieves revenue growth and stable operating profit in the first six months of 2024/25
Further recovery in order entry compared to prior year
JENA, 13 May 2025
Carl Zeiss Meditec generated revenue of €1,050.5m in the first half of fiscal year 2024/25 (prior year: €947.2m), including the DORC consolidation, corresponding ......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.05.2025
AFX
LISTED
XETR
Carl Zeiss Meditec erzielt Umsatzwachstum und stabilen operativen Gewinn im ersten Halbjahr 2024/25
News Preview
Carl Zeiss Meditec erzielt Umsatzwachstum und stabilen operativen Gewinn im ersten Halbjahr 2024/25
Auftragseingang gegenüber Vorjahr weiter erholt
JENA, 13. Mai 2025
Carl Zeiss Meditec erzielte in den ersten sechs Monaten des Geschäftsjahres 2024/25 inklusive der DORC-Konsolidierung einen Umsatz von rund 1.050,5 Millionen Euro (Vj. 947,2 ......
Themefolio
Profiler
Peergroup
© Globe Newswire
13.05.2025
GLPG
LISTED
EURONEXT
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes
News Preview
Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.05.2025
IBAB
LISTED
EURONEXT
IBA launches CASSY®, a new compact radiochemistry module to enhance efficiency in radiopharmaceuticals production
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.05.2025
ASND
LISTED
NASDAQ
New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
News Preview
COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide a durable response in adults with hypoparathyroidism. Results were shared in an oral present...
Themefolio
Profiler
Peergroup
© EQS Newswire
12.05.2025
ILM1
LISTED
XETR
Medios repositions itself for the next phase of its corporate development
News Preview
Press release
Medios repositions itself for the next phase of its corporate development
The company's founding team is leaving Medios at its own request
Matthias Gärtner hands over the CEO position to a successor after a transition period
Mi-Young Miehler (COO) will leave the company on 30 June 2025
Berlin, May 12, 2025 - Medios AG ("Medios"), ......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.05.2025
ILM1
LISTED
XETR
Medios stellt sich für die nächste Phase seiner Unternehmensentwicklung neu auf
News Preview
Pressemitteilung
Medios stellt sich für die nächste Phase seiner Unternehmensentwicklung neu auf
Das Gründungsteam des Unternehmens verlässt Medios auf eigenen Wunsch
Matthias Gärtner übergibt den Vorstandsvorsitz nach einer Übergangsphase an einen Nachfolger
Mi-Young Miehler (COO) verlässt das Unternehmen zum 30. Juni 2025
Berlin, 12. Mai 2025......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.05.2025
ILM1
LISTED
XETR
Changes to the Medios AG Executive Board; Matthias Gärtner will leave the company
News Preview
Changes to the Medios AG Executive Board; Matthias Gärtner will leave the company
Berlin, May 12, 2025 – Medios AG (“Medios”) today announces changes to its Executive Board: Matthias Gärtner, Chief Executive Officer (CEO), will step down as CEO at his own request after a transition period. He will remain in office until 31 December 2025 at the lat......
Themefolio
Profiler
Peergroup
© EQS Newswire
12.05.2025
ILM1
LISTED
XETR
Änderungen im Vorstand der Medios AG; Matthias Gärtner scheidet aus
News Preview
Änderungen im Vorstand der Medios AG; Matthias Gärtner scheidet aus
Berlin, 12. Mai 2025 – Die Medios AG ("Medios”) gibt heute Veränderungen im Vorstand bekannt: Matthias Gärtner, Vorstandsvorsitzender (CEO), übergibt den Vorstandsvorsitz auf eigenen Wunsch nach einer Übergangsphase an einen Nachfolger. Er ist noch bis längstens 31. Dezember 2025 ......
Themefolio
Profiler
Peergroup
© ActuNews
12.05.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 12 mei 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgevingen heeft ontvangen:
Oxurion ontving een transparant...
Themefolio
Profiler
Peergroup
© ActuNews
12.05.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – May 12, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
Oxurion received a transparency notification on May 9, 2025, from Atlas Spec...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.05.2025
IBAB
LISTED
EURONEXT
IBA – ACQUISITION OF OWN SHARES
News Preview
Immediate Release – May 12th, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.05.2025
FAGR
LISTED
EURONEXT
Fagron shareholders approve all voting items AGM
News Preview
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 May 2025 – 7PM CET...
Themefolio
Profiler
Peergroup
© EQS Newswire
12.05.2025
GXI
LISTED
XETR
Gerresheimer Successfully Completes Investment in State-of-the-Art Glass Production Facility in Lohr
News Preview
Gerresheimer Successfully Completes Investment in State-of-the-Art Glass Production Facility in Lohr
New oxy-hybrid furnace reduces CO2e emissions by up to 40%
Latest production technology and environmentally friendly cooling system
Capacity expansion to support planned growth
Total investment volume of approximately 100 million euros
Duesseldo......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
